<?xml version="1.0" encoding="UTF-8"?>
<p>Over the analysis period of 72 consecutive months, a total of 971 HCT (741 allo-HCT; 230 auto-HCT) were performed. Indications for HCTs were: acute lymphoblastic leukemia (ALL, 
 <italic>n</italic>=233), acute myeloblastic leukemia (AML, 
 <italic>n</italic>=151), neuroblastoma (
 <italic>n</italic>=138), primary immunodeficiencies (
 <italic>n</italic>=113), bone marrow failure syndromes (
 <italic>n</italic>=101), Non-Hodgkin Lymphoma and Hodgkin Lymphoma (NHL/HD, 
 <italic>n</italic>=65), Ewing sarcoma (
 <italic>n</italic>=44), myelodysplastic syndrome (
 <italic>n</italic>=38) and other indications (
 <italic>n</italic>=88).
</p>
